文献速递肝病

靶向肝脏ACSL4改善小鼠NASH

Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
PubMed 文献 · Hepatology · 2021-11-27

研究显示NAFLD患者肝脏ACSL4水平升高,抑制ACSL4可促进线粒体呼吸、增强脂肪酸β氧化并减少脂质蓄积,且低剂量abemaciclib作为选择性ACSL4抑制剂可显著改善多种NAFLD小鼠模型症状,提示抑制ACSL4是NAFLD潜在治疗策略。

要点

  • NAFLD患者肝脏ACSL4水平较健康对照升高
  • 抑制ACSL4通过上调PGC-1α促进线粒体呼吸和脂肪酸β氧化
  • 低剂量abemaciclib可显著改善多种NAFLD小鼠模型症状

核心结论

  • 抑制ACSL4是NAFLD的潜在替代治疗策略。

研究设计与样本

  • 研究比较NAFLD患者与健康对照的肝脏ACSL4水平,并在多种NAFLD小鼠模型中评估ACSL4抑制或abemaciclib的效果。

主要发现

  • NAFLD患者肝脏ACSL4水平较健康对照升高。
  • 抑制ACSL4表达促进线粒体呼吸,上调PGC-1α增强肝细胞脂肪酸β氧化能力并减少脂质蓄积。
  • 低剂量abemaciclib作为强效选择性ACSL4抑制剂,在多种NAFLD小鼠模型中显著改善多数NAFLD症状。

临床怎么用

  • 提示ACSL4可作为NAFLD治疗的潜在靶点,abemaciclib等ACSL4抑制剂值得进一步临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Globally, NAFLD is one of the most common liver disorders, with an estimated prevalence rate of more than 30% in men and 15% in women and an even higher prevalence in people with type 2 diabetes mellitus. Optimal pharmacologic therapeutic approaches for NAFLD are an urgent necessity. APPROACH AND RESULTS: In this study, we showed that compared with healthy controls, hepatic ACSL4 levels in patients with NAFLD were found to be elevated. Suppression of ACSL4 expression promoted mitochondrial respiration, thereby enhancing the capacity of hepatocytes to mediate β-oxidation of fatty acids and to minimize lipid accumulation by up-regulating peroxisome proliferator-activated receptor coactivator-1 alpha. Moreover, we found that abemaciclib is a potent and selective ACSL4 inhibitor, and low dose of abemaciclib significantly ameliorated most of the NAFLD symptoms in multiple NAFLD mice models. CONCLUSIONS: Therefore, inhibition of ACSL4 is a potential alternative therapeutic approach for NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Duan J, Wang Z, Duan R, et al. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. Hepatology. 2021. PMID: 34510514. doi:10.1002/hep.32148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。